C-TRACT: Iliac Vein Stenting Results Look Good in Postthrombotic Syndrome

Why It Matters

Stenting offers a clinically meaningful symptom reduction for a condition that affects up to 40% of DVT patients, potentially reshaping standard care despite a modest rise in bleeding risk.

Key Takeaways

• Iliac vein stenting cuts VCSS scores by 2 points at 6 months
• VEINES‑QOL improves 14.5 points versus standard care
• Bleeding risk rises to 11.6% with stenting versus 3.6% usual care
• No difference in recurrent VTE or mortality between treatment arms
• Long‑term durability and cost‑effectiveness of venous stents remain uncertain

Pulse Analysis

Post‑thrombotic syndrome (PTS) remains a frequent, debilitating sequel of deep‑vein thrombosis, affecting roughly 40% of patients and causing chronic leg swelling, pain, and ulceration. Historically, management has relied on compression therapy, anticoagulation, and lifestyle changes, yet robust data supporting more invasive interventions were scarce. The C‑TRACT trial, published in the New England Journal of Medicine, filled this gap by randomizing 225 moderate‑to‑severe PTS patients across 29 U.S. centers to either standard care or endovascular iliac vein stenting combined with intensified antithrombotic therapy, providing the first large‑scale evidence base for this approach.

The six‑month outcomes were striking: patients receiving stents experienced a two‑point reduction in the Venous Clinical Severity Score and a 14.5‑point jump in VEINES‑QOL scores, indicating substantial symptom relief and enhanced health‑related quality of life. These gains were mirrored in the SF‑36 health survey, which rose 6.1 points versus control. However, the trade‑off was a higher incidence of bleeding events—11.6% versus 3.6%—driven largely by non‑major bleeds linked to the intensified antithrombotic regimen. Importantly, the trial found no increase in recurrent venous thromboembolism or mortality, suggesting the safety profile remains acceptable when bleeding risks are managed.

Clinicians must now weigh these benefits against bleeding risks and consider individual patient factors such as age, gender, and reproductive plans. The study’s authors call for longer‑term data to confirm stent patency, durability, and cost‑effectiveness, as well as refined bleeding‑risk algorithms. As newer anticoagulants emerge, future trials may further optimize the balance between clot prevention and hemorrhage, potentially solidifying iliac vein stenting as a guideline‑endorsed option for carefully selected PTS patients.